eNavvi
Free digital prescribing platform for clinicians with real-time cash price visibility and e-prescription routing.
Website: https://enavvi.com
Cover Block
PUBLIC
| Field | Value |
|---|---|
| Name | eNavvi |
| Tagline | Free digital prescribing platform for clinicians with real-time cash price visibility and e-prescription routing |
| Stage | Seed |
| Business Model | SaaS |
| Industry | Healthtech |
| Technology | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Funding Label | Seed (total disclosed approximately $250,000) |
Links
PUBLIC
- Website: https://enavvi.com/home
- Formulary product: https://formulary.enavvi.com/
- LinkedIn: https://www.linkedin.com/company/enavvi
- Wefunder campaign: https://wefunder.com/enavvi
- Crunchbase: https://www.crunchbase.com/organization/enavvi
Executive Summary
PUBLIC
eNavvi is a clinician-facing digital prescribing platform that surfaces real-time cash prices for medications and routes electronic prescriptions to a national pharmacy network, positioning itself at the intersection of price transparency and physician workflow [eNavvi]. The company was founded by Simon Chang, DO, who serves as Co-Founder, CEO, and President, and has assembled a working group that skews heavily clinical, including multiple physicians on the team [Crunchbase]. The core product is offered free to prescribers and competes for attention against incumbents embedded in electronic medical record (EMR) systems by emphasizing transparent cash pricing and partnerships with low-cost pharmacy operators such as Mark Cuban's Cost Plus Drug Company [eNavvi]. Disclosed capital is modest: company materials report approximately $250,000 secured through direct investments closed April 30, 2025, alongside a Wefunder crowdfunding campaign, while CB Insights records an earlier $80,000 angel round backed by WeFunder [eNavvi, April 2025] [CBInsights]. In January 2026, eNavvi announced a partnership with SandsRx to expand sterile and non-sterile compounding for dermatology, weight management, and hormone replacement therapy, suggesting an early move toward higher-margin specialty workflows [PRNewswire, January 2026]. A redesigned product with full ePrescribing and EPCS (electronic prescribing of controlled substances) capabilities is publicly slated for May 2026, which will be the most consequential milestone to track [eNavvi]. Investors should weigh the company's clinician-led design and transparency thesis against the limited disclosed funding, the absence of confirmed revenue figures, and an unproven monetization path on a free-to-prescriber platform.
Data Accuracy: YELLOW -- Primary product and partnership claims are corroborated by company materials and PR Newswire, but funding totals diverge between eNavvi's site and CB Insights.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Seed |
| Business Model | SaaS (free to prescriber; monetization path not publicly detailed) |
| Industry / Vertical | Healthtech, ePrescribing, drug price transparency |
| Technology Type | Software (Non-AI) |
| Geography | North America |
| Growth Profile | Venture Scale |
| Funding | Seed, approximately $250,000 disclosed |
Company Overview
PUBLIC
eNavvi describes itself as a "pioneering start-up company" whose mission is to "empower clinicians with technology that reduces administrative burden, frustration, and healthcare costs" [eNavvi]. The company is led by Simon Chang, DO, a physician-founder whose LinkedIn lists clinical affiliation with Kaiser Permanente, and the platform is positioned as "designed by physicians for physicians" [LinkedIn] [eNavvi]. Public records do not confirm a headquarters city or year of incorporation, and the company's PitchBook profile is gated, which limits independent verification of legal entity details [PitchBook, 2026].
The earliest external trace of capital formation is a CB Insights record of an $80,000 angel round with WeFunder listed as an investor [CBInsights]. eNavvi's own crowdfunding page states that "$250K has already been secured through direct investments, closed April 30, 2025," with a further $500,000 healthcare crowdsourcing initiative and $250,000 reserved for strategic angel investors as part of an open round [eNavvi, April 2025]. A Substack write-up by Robert Ritch noted that the Wefunder campaign was open through September 30, 2024, suggesting that the raise has been staged across multiple windows [Investors Move].
The most concrete recent milestone is a January 2026 partnership with SandsRx to expand sterile and non-sterile compounding services across dermatology, weight management, and hormone replacement therapy categories [PRNewswire, January 2026] [Morningstar, 2026]. Company materials also pre-announce a redesigned platform with full ePrescribing and EPCS capabilities arriving May 2026, which would represent the platform's first push into controlled-substance workflows [eNavvi].
Data Accuracy: YELLOW -- Founding date and HQ are not in public sources; partnership and round milestones are corroborated across two outlets each.
Product and Technology
MIXED
The live product is a web-based formulary navigator and ePrescribing tool that lets prescribers compare drug prices across insurance and cash channels, view prior authorization requirements and step therapy protocols, and route prescriptions electronically to pharmacies nationwide [eNavvi]. eNavvi's FAQ describes the first product as "a formulary navigator that shows prescribers and patients how much a patient's drugs will cost and any requirements to prescribe it, among other useful data," framing it as a decision-support layer that sits adjacent to (rather than replacing) an EMR [eNavvi]. A pharmacy network page lists Mark Cuban Cost Plus Drug Company among partners, anchoring the cash-price thesis to a recognized low-cost supplier [eNavvi].
Product scope appears to be widening along two axes. First, eNavvi has begun publishing content on compounded topicals, noting that "insurance plans and PBMs typically do not adjudicate claims for compounded topicals" and positioning transparent cash pricing as the natural fit for that category [eNavvi]. The SandsRx partnership operationalizes that thesis in dermatology, weight management, and HRT [PRNewswire, January 2026]. Second, the company's DME page indicates that "a completely redesigned experience with full ePrescribing and EPCS capabilities arrives May 2026," which would extend coverage into durable medical equipment and controlled substances [eNavvi].
On the technology stack, no job postings were surfaced and the company has not published an engineering blog, so infrastructure choices, EMR integration depth, and data-sourcing methodology for real-time pricing are not publicly documented. EPCS in particular requires DEA-compliant identity proofing and two-factor authentication standards, so the May 2026 launch will be a meaningful test of regulatory readiness rather than a cosmetic refresh.
Data Accuracy: YELLOW -- Product features are confirmed on company surfaces and press releases; technical architecture and integration partners are not publicly disclosed.
Market Research and Opportunity
PUBLIC
Drug price transparency at the point of prescribing has moved from a niche concern to a federally encouraged workflow, and eNavvi sits in the slipstream of that shift. This section relies on directional context rather than a sized market estimate, as a third-party TAM figure specific to ePrescribing price-transparency tools is not available.
The demand drivers are visible in the company's own positioning. Cash-pay prescribing has grown materially as patients with high-deductible plans, uninsured populations, and users of GLP-1 and compounded medications increasingly bypass insurance adjudication. eNavvi's editorial content explicitly notes that "insurance plans and PBMs typically do not adjudicate claims for compounded topicals," creating a structural opening for cash-price comparison tools in categories that traditional formulary lookups inside an EMR do not serve well [eNavvi]. The Mark Cuban Cost Plus Drug Company partnership is itself a market signal: a high-profile entrant has validated direct-to-consumer cash pricing at scale, and downstream tools that surface those prices to prescribers benefit from the same wave [eNavvi].
Adjacent and substitute markets matter for how this opportunity is framed. The most direct substitute is the e-prescribing module already embedded inside major EMRs (Epic, Cerner, athenahealth and others) and the Surescripts Real-Time Prescription Benefit network that many of those EMRs consume. Adjacent categories include patient-facing discount card businesses (GoodRx being the most recognized public name), pharmacy-benefit transparency platforms aimed at employers, and direct-to-consumer pharmacies. eNavvi's specific wedge is the prescriber workstation, which is a different distribution surface from any of those adjacent businesses.
Regulatory tailwinds include the broader CMS push for real-time benefit tools and continued state-level scrutiny of pharmacy benefit manager pricing practices. Headwinds include EPCS compliance requirements, state-by-state e-prescribing mandates, and the practical reality that prescriber workflow change is slow when the existing EMR-embedded tool is "good enough" for covered medications.
| Market signal | Value | Source |
|---|---|---|
| Disclosed eNavvi seed capital | approximately $250,000 | [eNavvi, April 2025] |
| Pharmacy network anchor partner | Mark Cuban Cost Plus Drug Company | [eNavvi] |
| Specialty compounding partner | SandsRx (dermatology, weight management, HRT) | [PRNewswire, January 2026] |
Analyst takeaway: the table above is deliberately narrow because no third-party sized-market figure is in the public record for this specific niche; the more useful signal is the pattern of partner selection, which points eNavvi at cash-pay and compounded categories where incumbents are weakest rather than at insured-script volume where Surescripts-connected EMRs already dominate.
Data Accuracy: ORANGE -- Demand-driver narrative is supported by company content and one named partnership; no independent third-party TAM was located in the cited sources.
Competitive Landscape
MIXED
The competitive map for prescriber-facing transparency tools breaks into three layers. The first layer is the embedded e-prescribing module inside major EMRs, typically powered by the Surescripts Real-Time Prescription Benefit feed. This is the default workflow for most US prescribers and is the incumbent eNavvi must displace or supplement to win meaningful share in insured-script volume. The second layer is consumer-facing discount and price-comparison tools, the most visible of which is GoodRx; these reach the patient directly and arrive at the pharmacy counter rather than at the prescriber's screen. The third layer is direct-to-consumer pharmacy and compounding operators, including Mark Cuban Cost Plus Drug Company and a growing roster of GLP-1 and HRT specialty pharmacies, which compete on supply economics rather than on prescriber tooling.
eNavvi's defensible edge today rests on three observable choices. The platform is free to the prescriber, which lowers adoption friction relative to subscription tools [eNavvi]. It is positioned outside the EMR rather than inside it, which means it can show cash prices that EMR-embedded tools structurally underweight because their pricing feeds are insurance-centric. And the team is physician-led, with Simon Chang, DO and additional clinical contributors including Reddy Pathakota, MD, MBA, Alex Prevallet, DO, Kunal Joshi, MD, MBA, and Yair Saperstein listed publicly, which can shorten the credibility loop with prescriber early adopters [LinkedIn, 2026]. The durability of these edges is mixed: clinician credibility compounds, but a free-to-prescriber model needs a clearly articulated paid layer (employer, pharmacy, or pharma-sponsored) to justify venture-scale capital, and that layer is not yet publicly described.
The exposure is twofold. First, any incumbent EMR that decides to surface cash prices natively, or any Surescripts-adjacent service that adds a robust cash-price overlay, can erode the differentiation overnight for insured prescribing. Second, in the compounding and cash-pay specialty categories where eNavvi is now leaning (per the SandsRx partnership), the company will compete with vertically integrated DTC pharmacies that bundle the prescription, the medication, and the patient relationship into a single brand [PRNewswire, January 2026].
The most plausible 18-month scenario splits along the May 2026 product launch. Winner if EPCS goes live cleanly and the SandsRx-style specialty partnerships multiply: eNavvi becomes the default cash-pay prescribing surface for a small but loyal cohort of independent clinicians and specialty practices, and that cohort produces enough script volume to justify a Series A at a credible cash-price-transparency narrative. Loser if the May 2026 launch slips or EPCS certification proves operationally heavy: the platform stays a useful free lookup tool but loses the workflow primacy that turns a free user into a paying ecosystem.
Data Accuracy: ORANGE -- Competitor names in this section are analyst context rather than facts confirmed in the source set; eNavvi's own positioning claims are confirmed by company materials and one partnership press release.
Opportunity
PUBLIC
If eNavvi executes on its May 2026 redesign and continues stitching specialty pharmacy partnerships to a free prescriber-facing front end, the prize is becoming the default cash-price prescribing layer for the segment of US healthcare that has effectively exited insurance adjudication.
The headline opportunity. The single largest outcome eNavvi could plausibly become is the prescriber-side counterpart to what Mark Cuban Cost Plus Drug Company has built on the supply side: a recognized, physician-trusted, transparency-first brand that owns the prescribing moment for cash-pay medications. The cited evidence makes this reachable rather than aspirational because the Cost Plus Drugs partnership is already in place [eNavvi], the SandsRx specialty compounding partnership extends the model into three high-growth categories (dermatology, weight management, and HRT) [PRNewswire, January 2026], and the planned EPCS capability would bring controlled-substance prescribing into the same surface [eNavvi]. None of those steps requires displacing Epic or Cerner inside the hospital; they require winning the independent and specialty prescriber, a softer beachhead.
Growth scenarios.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| Specialty cash-pay default | eNavvi becomes the routine prescribing surface for GLP-1, HRT, dermatology compounding, and similar cash-pay categories | Successful scale-out of the SandsRx model to additional specialty pharmacies through 2026 | The SandsRx partnership is already announced and explicitly targets these three categories [PRNewswire, January 2026] |
| EPCS-enabled independent prescriber tool | Independent and small-group prescribers adopt eNavvi as their primary external e-prescribing tool because it shows cash prices their EMR does not | Clean launch of "full ePrescribing and EPCS capabilities" in May 2026 | The capability is publicly committed on the company's own DME page [eNavvi] |
| Pharma and pharmacy-funded transparency utility | Pharmaceutical manufacturers and cash-pay pharmacies pay to be surfaced inside the prescriber view, turning a free tool into a two-sided marketplace | Conversion of named pharmacy partners into paying placements after volume is demonstrated | A pharmacy network partners page already exists with named anchors including Cost Plus Drugs [eNavvi] |
What compounding looks like. The flywheel is straightforward and partly observable. Each new specialty pharmacy partner (SandsRx being the first publicly named in this category) adds inventory breadth, which makes the prescriber view more useful, which attracts more prescribers, which makes eNavvi a more attractive distribution surface for the next pharmacy. Physician-led credibility compounds in parallel: the team's publicly listed clinicians give the platform a credibility footprint inside specialty professional networks that a pure-tech competitor would have to buy. The data moat is the most uncertain piece, because real-time cash pricing depends on continued cooperation from pharmacy partners rather than on a proprietary dataset eNavvi owns outright.
The size of the win. A credible directional comparable is the public market value historically assigned to consumer-facing prescription price transparency: GoodRx Holdings reached a multi-billion-dollar public market capitalization on the back of cash-price comparison economics aimed at patients. eNavvi is targeting a different surface (the prescriber, not the patient) and a different mix (specialty and compounded as well as generic), which means the natural ceiling is a smaller addressable user base than GoodRx but a stickier one with higher script-level influence. If the specialty cash-pay default scenario plays out, a credible enterprise outcome (scenario, not a forecast) would be a category-leading prescriber transparency platform attractive to a strategic acquirer in pharmacy benefits, specialty pharmacy, or EMR distribution. The disclosed seed capital of approximately $250,000 [eNavvi, April 2025] is small relative to that ambition, which means the next financing round and its lead investor will be the clearest market verdict on whether the opportunity is being underwritten at venture scale.
Data Accuracy: YELLOW -- Scenarios are constructed from confirmed partnerships and publicly announced product milestones; the comparable to GoodRx is analyst context, not a forecast.
Sources
PUBLIC
[eNavvi] eNavvi | Free Digital Prescribing Platform for Clinicians | https://enavvi.com/home
[eNavvi] eNavvi formulary product | https://formulary.enavvi.com/
[eNavvi] eNavvi | Team | https://enavvi.com/team
[eNavvi] eNavvi | Mission | https://enavvi.com/mission
[eNavvi] eNavvi FAQ | https://formulary.enavvi.com/faq
[eNavvi] eNavvi | DME | https://enavvi.com/results/DME
[eNavvi] eNavvi | Pricing | https://enavvi.com/pricing
[eNavvi] eNavvi | Insights | https://enavvi.com/insights
[eNavvi] eNavvi | Pharmacy Network Partners | https://formulary.enavvi.com/partners
[eNavvi, April 2025] eNavvi | Crowdfunding | https://enavvi.com/Crowdfunding
[Wefunder] Invest in eNavvi | https://wefunder.com/enavvi
[Crunchbase] eNavvi Crunchbase Company Profile and Funding | https://www.crunchbase.com/organization/enavvi
[Crunchbase] Simon Chang Crunchbase Person Profile | https://www.crunchbase.com/person/simon-chang-9907
[LinkedIn] eNavvi LinkedIn company page | https://www.linkedin.com/company/enavvi
[LinkedIn] Simon Chang, DO LinkedIn profile | https://www.linkedin.com/in/simon-chang-do-b66749207/
[CBInsights] eNavvi Products, Competitors, Financials, Employees, Headquarters Locations | https://www.cbinsights.com/company/enavvi
[PitchBook, 2026] eNavvi 2026 Company Profile: Valuation, Funding and Investors | https://pitchbook.com/profiles/company/544765-87
[Investors Move] eNavvi by Robert Ritch | https://investorsmove.substack.com/p/enavvi
[PRNewswire, January 2026] eNavvi Partners with SandsRx to Expand Sterile and Non-Sterile Compounding for Dermatology, Weight Management, and HRT | https://www.prnewswire.com/news-releases/enavvi-partners-with-sandsrx-to-expand-sterile-and-non-sterile-compounding-for-dermatology-weight-management-and-hrt-302664304.html
[Morningstar, 2026] eNavvi Partners with SandsRx (PR Newswire syndication) | https://www.morningstar.com/news/pr-newswire/20260119la65855/enavvi-partners-with-sandsrx-to-expand-sterile-and-non-sterile-compounding-for-dermatology-weight-management-and-hrt
Articles about eNavvi
- eNavvi Wants Every Prescriber to See the Cash Price Before They Hit Send — The physician-built ePrescribing tool is courting clinicians frustrated by prior auth and surprise pharmacy bills.